Skip to main content
. 2021 Jun 15;11(6):2537–2567.

Figure 2.

Figure 2

ASPH promotes EMT and ECM degradation. A. Expression profiling of ASPH in human breast cancer cell lines. B. Expression of mesenchymal marker Vimentin affected by WT- vs. mutant-ASPH. C, D. Expression of epithelial marker E-cadherin modified by WT- vs. mutant- or KO-ASPH. E, F. Expression profiling of major components attributed to EMT in breast cancer cell lines. G-J. WT-ASPH augmented ECM degradation, which was reversed by mutant- or KO-ASPH. *P < 0.05; **P < 0.01; ***P < 0.001.